About Earli
Earli is a biotechnology company dedicated to transforming cancer detection and treatment. Their core mission is to make cancer a benign experience by leveraging cutting-edge science, engineering, and software to turn cancer against itself. The company has developed a “Synthetic Biopsy” technology that utilizes programmable genetic constructs. These constructs are designed to activate exclusively within cancer cells, forcing them to produce synthetic biomarkers that can be detected through existing imaging methods like PET scans and laboratory analyses.
This innovative approach aims to overcome the limitations of traditional liquid biopsies, which often struggle to detect the subtle signals of early-stage tumors. By making cancer cells reveal their location, Earli’s technology enables precise localization of early-stage tumors, allowing for targeted treatment before the cancer can mutate or metastasize. Earli’s platform also explores therapeutic applications, reprogramming cancer cells to produce immune-activating proteins that trigger self-destruction.
Earli’s work is rooted in the vision of co-founder Dr. Sam Gambhir, who sought to use cancer-activated gene expression to produce payloads useful for diagnosing early-stage malignancies. The company combines bioinformatics, machine learning, and empirical testing to generate synthetic promoters that selectively activate within cancer samples across diverse genetic backgrounds. This integration of biology, engineering, and software is central to their strategy for early cancer detection, localization, and the development of novel therapies.
Focus Areas
Business Intelligence
| Technology | Synthetic Biopsy platform using programmable genetic constructs, AI-driven bioinformatic analysis, machine learning for biomarker identification, multi-modal AI flywheel for programmable disease control |
What Physicians Need to Know
For physicians, Earli's technology offers the potential for unprecedented early cancer detection and precise localization, even for tumors that are currently undetectable. This could enable earlier intervention and more effective, personalized treatments, significantly improving patient outcomes and survival rates. The ability to force cancer cells to produce specific biomarkers could lead to highly sensitive and specific diagnostic tools, reducing false positives and negatives. Furthermore, the therapeutic applications being developed could offer novel treatment strategies that specifically target and eliminate cancer cells while minimizing harm to healthy tissue. Earli's technology is currently undergoing clinical trials, including in Australia, for patients with advanced lung cancer or other cancers with lung or liver metastases.
Earli's platform is built on technology licensed from Stanford University. They have received funding from notable investors such as Andreessen Horowitz's Bio Fund, Khosla Ventures, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, and ZhenFund. Accenture Ventures has also made a strategic investment, supporting collaborations with global health and pharma companies. Earli has utilized the Benchling platform for documenting critical early research, highlighting an integration with laboratory information management systems for data infrastructure. Their AI development includes building upon existing convolutional neural network models like ResNet and U-Net for medical image segmentation.
What the Web Says
Earli is a company focused on early cancer detection through a multi-cancer early detection (MCED) platform. Reviews suggest a strong scientific foundation and a mission-driven culture, but also highlight the early stage of their product and the inherent challenges of a startup environment.
Overall: PositiveStrengths
- Strong scientific foundation and innovative technology for early cancer detection.
- Mission-driven company with a passionate and intelligent team.
- Positive work environment with good benefits and a focus on employee well-being.
- Potential to make a significant impact on healthcare.
- Collaborative and supportive culture.
Limitations
- As a startup, there can be challenges with rapid changes and evolving priorities.
- The product is still in development, meaning limited external product reviews currently.
- Some reviews mention typical startup growing pains, such as occasional lack of clear processes.
- High expectations and demanding work environment due to the critical nature of their mission.
Based on reviews from: Glassdoor, LinkedIn (general sentiment from employee posts)
Last updated: 2026-10-27
Videos
News, demos, and interviews about Earli.
Videos load interactively. If none appear, search YouTube for Earli →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Earli.
Related Companies
TimeDoc Health is a healthcare technology and services company that provides virtual care management solutions, primarily focusing on chronic care management (CCM), remote patient monitoring (RPM), and behavioral health integration (BHI). Their platform and services are designed to help healthcare organizations, including primary care providers, health systems, FQHCs (Federally Qualified Health Centers), and Medicare Advantage […]
PMHScribe is an AI-powered clinical documentation tool specifically designed for psychiatrists, Psychiatric Mental Health Nurse Practitioners (PMHNPs), therapists, and other behavioral health clinicians. Unlike generic AI scribes, PMHScribe is built to understand the unique workflows and documentation requirements of mental healthcare, generating structured notes such as SOAP, DAP, and BIRP notes. The platform aims to […]
PHQ Screeners is a free, open-access resource maintained by Pfizer, providing a comprehensive suite of Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments. These tools were developed by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke with an educational grant from Pfizer, and are widely utilized in primary care and […]
MedLaunch is an AI-powered healthcare IT company that focuses on diagnosing and resolving operational inefficiencies in small to mid-size outpatient clinics, including general practice, specialty, and allied health. They aim to reduce administrative overhead, improve patient flow, and protect revenue through purpose-built AI solutions. MedLaunch emphasizes deep healthcare industry expertise, end-to-end digital solution implementation, and […]
Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]
CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]